FDA Approved: TEMODAR — Supplemental Application (Merck Sharp & Dohme LLC)

View source ↗

Summary

FDA approves a supplemental application for TEMODAR (temozolomide) submitted by Merck Sharp & Dohme LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Astrocytoma
• Glioblastoma Multiforme
• Malignant Glioma

Drugs mentioned

• Temodar (Temozolomide)

Snippet

SUPPL AP for TEMODAR (TEMOZOLOMIDE)